We are live on ! Find out more
FM

Frazier Management Portfolio holdings

AUM $1.12M
1-Year Est. Return 151.58%
This Fund
S&P 500
This Quarter Est. Return
-22.94%
1 Year Est. Return
+151.58%
3 Year Est. Return
+408.4%
5 Year Est. Return
+1,802.6%
10 Year Est. Return
–
AUM
$320M
AUM Growth
-$70.4M
Cap. Flow
+$36M
Cap. Flow %
11.25%
Top 10 Hldgs %
86.11%
Holding
19
New
1
Increased
1
Reduced
2
Closed
–
Avg Time Held
6.8 quarters
Top 10 Avg Time Held
6.6 quarters
Top 20 Avg Time Held
6.8 quarters

Top Buys

Rank Stock Value
1
MIRM icon
Mirum Pharmaceuticals
MIRM
+$43.8M
2
TBIO icon
Translate Bio, Inc. Common Stock
TBIO
+$4.72M

Top Sells

Rank Stock Value
1
IOVA icon
Iovance Biotherapeutics
IOVA
+$9.68M
2
SYBX icon
Synlogic
SYBX
+$2.81M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
ANAB icon
1
AnaptysBio
ANAB
$1.36B
$81.1M 25.34%
2,316,447
– –
2017 Q1
10 quarters
MIRM icon
2
Mirum Pharmaceuticals
MIRM
$5.17B
$35.9M 11.22%
+3,566,912
New +$43.8M
2019 Q3
0 quarters
IOVA icon
3
Iovance Biotherapeutics
IOVA
$6.57B
$31.9M 9.96%
1,750,665
-437,666
-20% -$9.68M
2016 Q2
13 quarters
KRYS icon
4
Krystal Biotech
KRYS
$9.51B
$31.1M 9.72%
895,000
– –
2018 Q3
4 quarters
COLL icon
5
Collegium Pharmaceutical
COLL
$701M
$21.7M 6.77%
1,887,332
– –
2015 Q4
15 quarters
TBIO icon
6
DELISTED
Translate Bio, Inc. Common Stock
TBIO
$21.6M 6.76%
2,182,789
+500,000
+30% +$4.72M
2019 Q2
1 quarter
GRTS icon
7
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
$17.8M 5.57%
2,061,758
– –
2018 Q3
4 quarters
ALNA
8
DELISTED
Allena Pharmaceuticals
ALNA
$13.1M 4.1%
3,330,373
– –
2017 Q4
7 quarters
APTX
9
DELISTED
Aptinyx Inc. Common Stock
APTX
$11.1M 3.48%
3,190,079
– –
2018 Q2
5 quarters
ALPN icon
10
DELISTED
Alpine Immune Sciences Inc
ALPN
$10.2M 3.18%
2,571,450
– –
2017 Q3
8 quarters
TPST icon
11
Tempest Therapeutics
TPST
$11.5M
$9.93M 3.1%
7,162
– –
2018 Q4
3 quarters
ITRM icon
12
DELISTED
Iterum Therapeutics
ITRM
$8.88M 2.78%
102,554
– –
2018 Q2
5 quarters
NBRV
13
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
$8.51M 2.66%
17,026
– –
2018 Q3
4 quarters
ETTX
14
DELISTED
Entasis Therapeutics Holdings Inc.
ETTX
$8.05M 2.52%
1,349,953
– –
2018 Q3
4 quarters
SRRA
15
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$3.17M 0.99%
202,803
– –
2015 Q4
15 quarters
CDTX icon
16
DELISTED
Cidara Therapeutics
CDTX
$2.62M 0.82%
65,613
– –
2015 Q4
15 quarters
KZR icon
17
DELISTED
Kezar Life Sciences
KZR
$1.53M 0.48%
46,774
– –
2018 Q2
5 quarters
BLCM
18
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
$1.1M 0.35%
105,144
– –
2018 Q2
5 quarters
SYBX icon
19
DELISTED
Synlogic
SYBX
$647K 0.2%
18,843
-38,851
-67% -$2.81M
2018 Q1
6 quarters

Similar funds

ACMV
August Capital Management VI Palo Alto, California $1.39M AUM
FRCMI
First Round Capital Management III Philadelphia, Pennsylvania $418K AUM
DB
DCVC Bio Palo Alto, California $313K AUM
NAM
Newfleet Asset Management Hartford, Connecticut $2.05M AUM 27.28% 1-Year Est. Return
AP
Atlas Principals Charlotte, North Carolina $2.19M AUM 56.71% 1-Year Est. Return
ID
Inspire Developers Forest Hills, New York $4.07M AUM
CI
CMT Investments Chicago, Illinois $5M AUM 15.27% 1-Year Est. Return
DIF
Discovery Investment Fund Singapore $6.98M AUM

Frazier Management's Q3 2019 Portfolio in Review

As of Q3 2019, Frazier Management held 19 positions worth $320M, down 18% from $390M the previous quarter. Its ten largest holdings account for 86% of the portfolio.

Frazier Management deployed $36M of net new capital in Q3 2019, opening 1 new position and adding to 1 existing holding. Its largest new stake was Mirum Pharmaceuticals: 3,566,912 shares worth $35.9M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was Iovance Biotherapeutics, an estimated $9.68M trimmed.

  • Frazier Management's largest Q3 2019 buy was Mirum Pharmaceuticals: 3,566,912 shares worth $35.9M.
  • Frazier Management added most to Translate Bio, Inc. Common Stock in Q3 2019, an estimated $4.72M increase.
  • Frazier Management's biggest Q3 2019 reduction was Iovance Biotherapeutics, cutting an estimated $9.68M.
  • Frazier Management's ten largest holdings make up 86% of its $320M portfolio in Q3 2019.
  • Frazier Management opened 1 new position and closed 0 in Q3 2019.
  • Frazier Management's portfolio value fell 18% quarter-over-quarter to $320M.

Based on Frazier Management's 13F filing for Q3 2019, filed 12 Nov 2019.